tiprankstipranks
Trending News
More News >
Zealand Pharma (ZLDPF)
OTHER OTC:ZLDPF
US Market
Advertisement

Zealand Pharma (ZLDPF) Earnings Dates, Call Summary & Reports

Compare
186 Followers

Earnings Data

Report Date
Feb 19, 2026
TBA (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-1.26
Last Year’s EPS
-0.63
Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 13, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial performance and significant advancements in the pipeline, especially in obesity management. However, challenges in the manufacturing of dasiglucagon and the pause in dapiglutide development were noted. The overall sentiment reflects optimism about partnerships and upcoming data readouts, despite some setbacks.
Company Guidance
During the Zealand Pharma Q3 2025 earnings call, the company provided several key updates and forward-looking statements about its ongoing projects and financial performance. The call highlighted Zealand's progress with the petrelintide Phase II ZUPREME-1 trial, anticipating the 42-week top-line data release in the first half of 2026. Additionally, Zealand expects results from the 76-week SYNCHRONIZE-1 Phase III trial for survodutide in the same timeframe. Financially, Zealand reported a revenue of DKK 9.1 billion for the first nine months of 2025, primarily from an upfront payment from its collaboration with Roche, and a cash position of DKK 16.2 billion as of September 30, 2025. The company also narrowed its net operating expenses guidance to between DKK 2 billion and DKK 2.3 billion for the year, following the decision to pause the dapiglutide development. The call emphasized Zealand's strategic focus on the amylin-based therapy petrelintide and its potential to lead in weight management, as well as its collaboration with Roche aimed at redefining future obesity treatments.
Strong Execution and Milestones
Achieved a key milestone in the petrelintide Phase II ZUPREME-1 trial in obesity. Rapidly approaching data from several Phase III trials with survodutide in obesity.
Financial Performance and Position
Revenue for the first 9 months of 2025 was DKK 9.1 billion, primarily from the initial upfront payment from Roche. Cash position increased to DKK 16.2 billion as of September 30, 2025.
Partnerships and Collaborations
Continued momentum in the partnership with Roche. Positive engagement with Boehringer Ingelheim in obesity management.
Pipeline Advancements
Phase III SYNCHRONIZE program of survodutide in obesity consists of 6 trials expected to complete in 2026. Encouraged by the clinical profile of glepaglutide for short bowel syndrome.

Zealand Pharma (ZLDPF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ZLDPF Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 19, 2026
2025 (Q4)
-1.26 / -
-0.633
Nov 13, 2025
2025 (Q3)
-1.23 / -0.89
-0.579-53.33% (-0.31)
Aug 14, 2025
2025 (Q2)
16.87 / 16.30
-0.712396.37% (+17.01)
May 08, 2025
2025 (Q1)
-0.34 / -0.73
-0.573-28.03% (-0.16)
Feb 20, 2025
2024 (Q4)
-0.79 / -0.63
-0.6898.17% (+0.06)
Nov 07, 2024
2024 (Q3)
-0.55 / -0.58
0.196-395.28% (-0.77)
Aug 15, 2024
2024 (Q2)
-0.62 / -0.71
-0.84916.38% (+0.14)
May 16, 2024
2024 (Q1)
-0.60 / -0.57
-0.592.88% (+0.02)
Feb 27, 2024
2023 (Q4)
-0.60 / -0.69
-0.80113.97% (+0.11)
Nov 09, 2023
2023 (Q3)
-0.36 / 0.20
-0.654129.95% (+0.85)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ZLDPF Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2025
$78.72$80.50+2.26%
Aug 14, 2025
$53.68$55.02+2.50%
May 08, 2025
$68.22$63.26-7.27%
Feb 20, 2025
$108.08$106.34-1.61%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zealand Pharma (ZLDPF) report earnings?
Zealand Pharma (ZLDPF) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).
    What is Zealand Pharma (ZLDPF) earnings time?
    Zealand Pharma (ZLDPF) earnings time is at Feb 19, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ZLDPF EPS forecast?
          ZLDPF EPS forecast for the fiscal quarter 2025 (Q4) is -1.26.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis